International Consensus Statement on Rhinology and Allergy: Rhinosinusitis

Background: The 5 years since the publication of the first International Consensus Statement on Allergy and Rhinology: Rhinosinusitis (ICAR‐RS) has witnessed foundational progress in our understanding and treatment of rhinologic disease. These advances are reflected within the more than 40 new topics covered within the ICAR‐RS‐2021 as well as updates to the original 140 topics. This executive summary consolidates the evidence‐based findings of the document. Methods: ICAR‐RS presents over 180 topics in the forms of evidence‐based reviews with recommendations (EBRRs), evidence‐based reviews, and literature reviews. The highest grade structured recommendations of the EBRR sections are summarized in this executive summary. Results: ICAR‐RS‐2021 covers 22 topics regarding the medical management of RS, which are grade A/B and are presented in the executive summary. Additionally, 4 topics regarding the surgical management of RS are grade A/B and are presented in the executive summary. Finally, a comprehensive evidence‐based management algorithm is provided. Conclusion: This ICAR‐RS‐2021 executive summary provides a compilation of the evidence‐based recommendations for medical and surgical treatment of the most common forms of RS

Pre-market approval and post-market direct-to-consumer advertising of medical devices in Australia: a case study of breast cancer screening and diagnostic devices

While research investigating direct-to-consumer advertising of therapeutic goods in Australia has historically focused on prescription medicines, recent action taken by regulators against companies promoting medical devices has placed the industry into the spotlight. Despite the need to effectively regulate direct-to-consumer advertising of medical devices due to its potential harms, inadequacies in the current regulatory system have been noted. Under the present system, devices with a questionable evidence base may enter the Australian marketplace without an evaluation of their effectiveness, and regulators are reliant on industry self-regulation and consumer complaints to draw attention to cases of advertising misconduct. Although some successes in the present system have been observed, we argue that the outlined inadequacies continue to enable the promotion of medical devices to consumers without thorough or sufficient examination of evidence.T. D. Vreugdenburg, C. D. Willis, L. Mundy and J. E. Hille

Bulletin of the American Meteorological Society : BAMS

The objective of this study aimed to systematically identify and evaluate all the available evidence of safety, effectiveness and diagnostic accuracy for three emerging classes of technology promoted for breast cancer screening and diagnosis: Digital infrared thermal imaging (DITI), electrical impedance scanning (EIS) and elastography. A systematic search of seven biomedical databases (EMBASE, PubMed, Web of Science, CRD, CINAHL, Cochrane Library, Current Contents Connect) was conducted through March 2011, along with a manual search of reference lists from relevant studies. The principal outcome measures were safety, effectiveness, and diagnostic accuracy. Data were extracted using a standardised form, and validated for accuracy by the secondary authors. Study quality was appraised using the quality assessment of diagnostic accuracy studies tool, while heterogeneity was assessed using forest plots, Cooks’ distance and standardised residual scatter plots, and I2 statistics. From 6,808 search results, 267 full-text articles were assessed, of which 60 satisfied the inclusion criteria. No effectiveness studies were identified. Only one EIS screening accuracy study was identified, while all other studies involved symptomatic populations. Significant heterogeneity was present among all device classes, limiting the potential for metaanalyses. Sensitivity and specificity varied greatly for DITI (Sens 0.25–0.97, Spec 0.12–0.85), EIS (Sens 0.26–0.98, Spec 0.08–0.81) and ultrasound elastography (Sens 0.35–1.00, Spec 0.21–0.99). It is concluded that there is currently insufficient evidence to recommend the use of these technologies for breast cancer screening. Moreover, the high level of heterogeneity among studies of symptomatic women limits inferences that may be drawn regarding their use as diagnostic tools. Future research employing standardised imaging, research and reporting methods is required.Thomas D. Vreugdenburg, Cameron D. Willis, Linda Mundy and Janet E. Hille

RMCSat: An F10.7 Solar Flux Index CubeSat Mission

The F10.7 solar flux index is a measure of microwave solar emissions at a wavelength of 10.7 cm or 2800 MHz. It is widely used in thermosphere and ionosphere models as an indicator of solar activity and is recorded at only one terrestrial observatory in Penticton, Canada during daylight hours. The lack of geographical and temporal coverage of F10.7 measurements and no external redundancy to the existing system has led to the development of the RMCSat mission, which seeks to demonstrate the feasibility of collecting microwave solar flux emissions from a space-based platform. RMCSat is the first CubeSat mission by the Royal Military College of Canada. It offers a training environment for personnel in space mission analysis and design, satellite assembly, integration and testing, and satellite operations. This paper introduces the mission concept and preliminary design of a space-based solution that captures solar density flux measurements during each orbit as the Sun passes through the boresight of the primary payload antenna. In addition to two channels recording the 2800 MHz frequency (2785 MHz and 2815 MHz), a third channel records 2695 MHz using the same calibration standard to determine if the United States Radio Solar Telescope Network (RSTN) could be leveraged to supplement the existing F10.7 solar flux measurements and improve solar flux approximations. The RMCSat mission, satellite design, and system budgets are demonstrated here as being viable. Future design considerations pertain to the payload antennas and achievable launch orbits

Cover:Cover SEPT

Synopsis Iron ore fines are agglomerated to produce sinter, which is an important feed material for blast furnaces worldwide. A model of the iron ore sintering process has been developed with the objective of being representative of the sinter pot test, the standard laboratory process in which the behaviour of specific sinter feed mixtures is evaluated. The model aims to predict sinter quality, including chemical quality and physical strength, as well as key sinter process performance parameters such as production rate and fuel consumption rate. The model uses the finite difference method (FDM) to solve heat and mass distributions within the sinter pot over the height and time dimensions. This model can further be used for establishing empirical relationships between modelled parameters and measured sinter properties. Inputs into the model include the feed material physical properties, chemical compositions, and boundary conditions. Submodels describe relationships between applied pressure differential and gas flow rate through the bed of granulated fine ore particles, combustion of carbonaceous material, calcination of fluxes, evaporation and condensation of water, and melting and solidification. The model was applied to typical sinter test conditions to illustrate the results predicted, and to test sensitivities to parameters such as feed void fraction, feed coke percentage, and the fraction of combustion heat transferred to the gas phase. A model validation and improvement study should follow, ensuring sinter test results are free from experimental errors by conducting repeated tests